Switch to:

Castle Biosciences EV-to-Revenue

: 13.26 (As of Today)
View and export this data going back to 2019. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Castle Biosciences's enterprise value is USD829.09 Mil. Castle Biosciences's Revenue for the trailing twelve months (TTM) ended in Jun. 2020 was USD62.54 Mil. Therefore, Castle Biosciences's EV-to-Revenue for today is 13.26.

NAS:CSTL' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.1   Med: 8.5   Max: 11.8
Current: 13.26

4.1
11.8

During the past 3 years, the highest EV-to-Revenue of Castle Biosciences was 11.80. The lowest was 4.10. And the median was 8.50.

NAS:CSTL's EV-to-Revenue is ranked lower than
70% of the 219 Companies
in the Medical Diagnostics & Research industry.

( Industry Median: 7.25 vs. NAS:CSTL: 13.26 )

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2020-09-29), Castle Biosciences's stock price is USD50.00. Castle Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2020 was USD3.72. Therefore, Castle Biosciences's PS Ratio for today is 13.45.


Castle Biosciences EV-to-Revenue Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Castle Biosciences Annual Data
Dec17 Dec18 Dec19
EV-to-Revenue 0.00 0.00 9.93

Castle Biosciences Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
EV-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 5.24 9.93 8.01 0.00

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Castle Biosciences EV-to-Revenue Distribution

* The bar in red indicates where Castle Biosciences's EV-to-Revenue falls into.



Castle Biosciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Castle Biosciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=829.090/62.543
=13.26

Castle Biosciences's current Enterprise Value is USD829.09 Mil.
Castle Biosciences's Revenue for the trailing twelve months (TTM) ended in Jun. 2020 was 14.775 (Sep. 2019 ) + 17.635 (Dec. 2019 ) + 17.418 (Mar. 2020 ) + 12.715 (Jun. 2020 ) = USD62.54 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Castle Biosciences  (NAS:CSTL) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Castle Biosciences's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=50.00/3.717
=13.45

Castle Biosciences's share price for today is USD50.00.
Castle Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2020 was 1.033 (Sep. 2019 ) + 1.029 (Dec. 2019 ) + 0.93 (Mar. 2020 ) + 0.725 (Jun. 2020 ) = USD3.72.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Castle Biosciences EV-to-Revenue Related Terms


Castle Biosciences EV-to-Revenue Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)